Genetics and Therapies for GM2 Gangliosidosis.
Cachon-Gonzalez MB, Zaccariotto E, Cox TM.
Curr Gene Ther. 2018;18(2):68-89. doi: 10.2174/1566523218666180404162622.
Senescence-associated beta-galactosidase is lysosomal beta-galactosidase.
Lee BY, Han JA, Im JS, Morrone A, Johung K, Goodwin EC, Kleijer WJ, DiMaio D, Hwang ES.
Aging Cell. 2006 Apr;5(2):187-95. doi: 10.1111/j.1474-9726.2006.00199.x.
[GM2 gangliosidosis].
Tsuji S.
Ryoikibetsu Shokogun Shirizu. 1999;(27 Pt 2):177-9.
Efficacy and safety of miglustat in the treatment of GM2 gangliosidosis: A systematic review.
Mansouri V, Tavasoli AR, Khodarahmi M, Dakkali MS, Daneshfar S, Ashrafi MR, Heidari M, Hosseinpour S, Sharifianjazi F, Bemanalizadeh M.
Eur J Neurol. 2023 Sep;30(9):2919-2945. doi: 10.1111/ene.15871. Epub 2023 Jun 8.
Evaluation of the Landscape of Pharmacodynamic Biomarkers in GM1 and GM2 Gangliosidosis.
Stern S, Crisamore K, Li RJ, Pacanowski M, Schuck R.
Clin Transl Sci. 2025 Mar;18(3):e70176. doi: 10.1111/cts.70176.
Pharmacological Chaperones for beta-Galactosidase Related to G(M1) -Gangliosidosis and Morquio B: Recent Advances.
Stütz AE, Thonhofer M, Weber P, Wolfsgruber A, Wrodnigg TM.
Chem Rec. 2021 Nov;21(11):2980-2989. doi: 10.1002/tcr.202100269. Epub 2021 Nov 23.
[GM1 gangliosidosis--case report].
Obradović S, Laban O, Igrutinović Z, Vuletić B, Vujić A, Dindić J.
Med Pregl. 2010 May-Jun;63(5-6):427-30. doi: 10.2298/mpns1006427o.
Clinical and imaging predictors of late-onset GM2 gangliosidosis: A scoping review.
Godbole NP, Haxton E, Rowe OE, Locascio JJ, Schmahmann JD, Eichler FS, Ratai EM, Stephen CD.
Ann Clin Transl Neurol. 2024 Jan;11(1):207-224. doi: 10.1002/acn3.51947. Epub 2023 Nov 27.
[GM2 gangliosidosis].
Tanaka A.
Ryoikibetsu Shokogun Shirizu. 2001;(33):758-60.
GM1 gangliosidosis: patients with different phenotypic features and novel mutations.
Emecen Sanli M, Dogan M.
J Pediatr Endocrinol Metab. 2023 Apr 13;36(6):602-607. doi: 10.1515/jpem-2022-0630. Print 2023 Jun 27.
